Abstract
The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced fasting glucose, insulin and glycated haemoglobin and they delay the progression of insulin resistance/impaired glucose tolerance into T2DM. It is well recognized that adequate glycaemic control and subsequent amelioration of hyperinsulinaemia and hyperglycaemia can delay the onset of vascular complications. TZDs, however, also have a number of anti-atherogenic effects independent of their influences on glucose and insulin metabolism. They improve lipid profiles, lower blood pressure, have anti-inflammatory properties, improve endothelial function and increase large artery compliance in patients with type 2 diabetes mellitus. When compared to rosiglitazone, pioglitazone has more favourable effects on the lipid profiles of patients with T2DM. The disease preventive actions of TZDs may be the result of their agonistic effects on peroxisome proliferator-activated receptors (PPARs), ligand-activated transcription factors that regulate the expression of numerous genes and affect metabolism and vascular parameters. Thiazolidinediones, provide an effective treatment for populations with insulin resistance which is at high risk of developing cardiovascular disease. This paper discusses the differences between ROS and PIO and explores their antiatherogenic effects with particular focus on post-menopausal women with type 2 diabetes mellitus.
Keywords: Diabetes, Thiazolidinediones, Lipids, Endothelium, Menopause
Current Diabetes Reviews
Title: The Anti-Atherogenic Effects of Thiazolidinediones
Volume: 3 Issue: 1
Author(s): Lily Stojanovska, Suzy Y. Honisett and Paul A. Komesaroff
Affiliation:
Keywords: Diabetes, Thiazolidinediones, Lipids, Endothelium, Menopause
Abstract: The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced fasting glucose, insulin and glycated haemoglobin and they delay the progression of insulin resistance/impaired glucose tolerance into T2DM. It is well recognized that adequate glycaemic control and subsequent amelioration of hyperinsulinaemia and hyperglycaemia can delay the onset of vascular complications. TZDs, however, also have a number of anti-atherogenic effects independent of their influences on glucose and insulin metabolism. They improve lipid profiles, lower blood pressure, have anti-inflammatory properties, improve endothelial function and increase large artery compliance in patients with type 2 diabetes mellitus. When compared to rosiglitazone, pioglitazone has more favourable effects on the lipid profiles of patients with T2DM. The disease preventive actions of TZDs may be the result of their agonistic effects on peroxisome proliferator-activated receptors (PPARs), ligand-activated transcription factors that regulate the expression of numerous genes and affect metabolism and vascular parameters. Thiazolidinediones, provide an effective treatment for populations with insulin resistance which is at high risk of developing cardiovascular disease. This paper discusses the differences between ROS and PIO and explores their antiatherogenic effects with particular focus on post-menopausal women with type 2 diabetes mellitus.
Export Options
About this article
Cite this article as:
Stojanovska Lily, Honisett Y. Suzy and Komesaroff A. Paul, The Anti-Atherogenic Effects of Thiazolidinediones, Current Diabetes Reviews 2007; 3 (1) . https://dx.doi.org/10.2174/157339907779802058
DOI https://dx.doi.org/10.2174/157339907779802058 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with an increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to microcirculatory disturbances and reduced levels of endogenous growth factors. Delayed cutaneous wound healing is a chronic ...read more
Advancing Insights into Type 1 Diabetes: From Mechanisms to Management
Type 1 diabetes (T1D) represents a significant global health challenge, requiring a deep understanding of its complex pathophysiology and the development of innovative strategies for prevention, treatment, and management. This thematic issue highlights the latest progress in understanding the autoimmune processes underlying T1D, advances in beta-cell biology, and novel therapeutic ...read more
Oxidative and Inflammatory Responses in the Development of Secondary Diabetic Complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Current Drug Targets Diabetic Medications in Pregnancy
Current Diabetes Reviews Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Graphical Abstracts
Current Drug Delivery Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Current Signal Transduction Therapy Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
Medicinal Chemistry Insulin Releasing Properties of the Temporin Family of Antimicrobial Peptides
Protein & Peptide Letters Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Current Topics in Medicinal Chemistry Active Subfractions, Phytochemical Constituents, Dipeptidyl Peptidase-IV Inhibitory Activity and Antioxidant of Leaf Extract from Hibiscus surattensis L.
The Natural Products Journal Insights into the Role of DNA Methylation and Protein Misfolding in Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology subject Index To Volume 2
Current Gene Therapy A Review of Pharmacokinetic Parameters of Metabolites and Prodrugs
Drug Metabolism Letters